In order to experimentally distinguish Smad2 and Smad3 target sites, Smad2 and Smad3 fusion proteins were transfected into the breast cancer cell line MDA-MB-231 in a native cis-regulatory environment as BAC transgenes [18]. This evidence concerns the gene SMAD2 and breast carcinoma.